[email protected]
Int'l: +1(917)-997-2424
+91 916-916-4321
TRACK YOUR ORDER
CART ITEM
(0)
HOME
ABOUT US
REPORTS STORE
CONTACT US
Search by Text
Search by Report Code
Search
Home
Customize Purchase
Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Insights and Forecast to 2028
Chapter/Section Purchase
Back to Report
Leave This Empty:
Report Title:-
Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Insights and Forecast to 2028
Choose Chapter/Section to Purchase
Chapter/Section 1
Chapter/Section 2
Chapter/Section 3
Chapter/Section 4
Chapter/Section 5
Chapter/Section 6
Chapter/Section 7
Chapter/Section 8
Chapter/Section 9
Chapter/Section 10
Chapter/Section 11
Chapter/Section 12
Chapter/Section 13
Chapter/Section 14
Chapter/Section 15
Full Name
*
:
Business Email
*
:
Company Name
*
:
Contact Number
*
:
Country
*
:
Select Country
Afghanistan (+93)
Albania (+355)
Algeria (+213)
American Samoa (+1684)
Andorra (+376)
Angola (+244)
Anguilla (+1264)
Antarctica (+0)
Antigua and Barbuda (+1268)
Argentina (+54)
Armenia (+374)
Aruba (+297)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas (+1242)
Bahrain (+973)
Bangladesh (+880)
Barbados (+1246)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bermuda (+1441)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Bouvet Island (+0)
Brazil (+55)
British Indian Ocean Territory (+246)
Brunei Darussalam (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Cayman Islands (+1345)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China (+86)
Christmas Island (+61)
Cocos (Keeling) Islands (+672)
Colombia (+57)
Comoros (+269)
Congo (+242)
Congo, the Democratic Republic of the (+242)
Cook Islands (+682)
Costa Rica (+506)
Cote D'Ivoire (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+1767)
Dominican Republic (+1809)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Falkland Islands (Malvinas) (+500)
Faroe Islands (+298)
Fiji (+679)
Finland (+358)
France (+33)
French Guiana (+594)
French Polynesia (+689)
French Southern Territories (+0)
Gabon (+241)
Gambia (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Gibraltar (+350)
Greece (+30)
Greenland (+299)
Grenada (+1473)
Guadeloupe (+590)
Guam (+1671)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Heard Island and Mcdonald Islands (+0)
Holy See (Vatican City State) (+39)
Honduras (+504)
Hong Kong (+852)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran, Islamic Republic of (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+1876)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, Democratic People's Republic of (+850)
Korea, Republic of (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Lao People's Democratic Republic (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libyan Arab Jamahiriya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macao (+853)
Macedonia, the Former Yugoslav Republic of (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Martinique (+596)
Mauritania (+222)
Mauritius (+230)
Mayotte (+269)
Mexico (+52)
Micronesia, Federated States of (+691)
Moldova, Republic of (+373)
Monaco (+377)
Mongolia (+976)
Montserrat (+1664)
Morocco (+212)
Mozambique (+258)
Myanmar (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
Netherlands Antilles (+599)
New Caledonia (+687)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Niue (+683)
Norfolk Island (+672)
Northern Mariana Islands (+1670)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Palestinian Territory, Occupied (+970)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Pitcairn (+0)
Poland (+48)
Portugal (+351)
Puerto Rico (+1787)
Qatar (+974)
Reunion (+262)
Romania (+40)
Russian Federation (+70)
Rwanda (+250)
Saint Helena (+290)
Saint Kitts and Nevis (+1869)
Saint Lucia (+1758)
Saint Pierre and Miquelon (+508)
Saint Vincent and the Grenadines (+1784)
Samoa (+684)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia and Montenegro (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
South Georgia and the South Sandwich Islands (+0)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Svalbard and Jan Mayen (+47)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syrian Arab Republic (+963)
Taiwan, Province of China (+886)
Tajikistan (+992)
Tanzania, United Republic of (+255)
Thailand (+66)
Timor-Leste (+670)
Togo (+228)
Tokelau (+690)
Tonga (+676)
Trinidad and Tobago (+1868)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+7370)
Turks and Caicos Islands (+1649)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
United States Minor Outlying Islands (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Venezuela (+58)
Viet Nam (+84)
Virgin Islands, British (+1284)
Virgin Islands, U.s. (+1340)
Wallis and Futuna (+681)
Western Sahara (+212)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Security Code
*
:
Submit
List of Chapters/Sections(Table Of Content)
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Agonist
1.2.3 Allosteric Modulator
1.2.4 Kinase Inhibitor
1.2.5 Monoclonal Antibody
1.2.6 Others
1.3 Market by Application
1.3.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Perspective (2017-2028)
2.2 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Growth Trends by Region
2.2.1 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Historic Market Size by Region (2017-2022)
2.2.3 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Forecasted Market Size by Region (2023-2028)
2.3 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Dynamics
2.3.1 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Industry Trends
2.3.2 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Drivers
2.3.3 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Challenges
2.3.4 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Players by Revenue
3.1.1 Global Top Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Players by Revenue (2017-2022)
3.1.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue
3.4 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Concentration Ratio
3.4.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue in 2021
3.5 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Key Players Head office and Area Served
3.6 Key Players Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product Solution and Service
3.7 Date of Enter into Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Breakdown Data by Type
4.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Historic Market Size by Type (2017-2022)
4.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Forecasted Market Size by Type (2023-2028)
5 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Breakdown Data by Application
5.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Historic Market Size by Application (2017-2022)
5.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size (2017-2028)
6.2 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Type
6.2.1 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Type (2017-2022)
6.2.2 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Type (2023-2028)
6.2.3 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Type (2017-2028)
6.3 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Application
6.3.1 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Application (2017-2022)
6.3.2 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Application (2023-2028)
6.3.3 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Application (2017-2028)
6.4 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country
6.4.1 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2017-2022)
6.4.2 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size (2017-2028)
7.2 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Type
7.2.1 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Type (2017-2022)
7.2.2 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Type (2023-2028)
7.2.3 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Type (2017-2028)
7.3 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Application
7.3.1 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Application (2017-2022)
7.3.2 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Application (2023-2028)
7.3.3 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Application (2017-2028)
7.4 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country
7.4.1 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2017-2022)
7.4.2 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size (2017-2028)
8.2 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Type
8.2.1 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Type (2017-2028)
8.3 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Application
8.3.1 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Application (2017-2028)
8.4 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Region
8.4.1 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size (2017-2028)
9.2 Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Type
9.2.1 Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Type (2017-2022)
9.2.2 Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Type (2023-2028)
9.2.3 Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Type (2017-2028)
9.3 Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Application
9.3.1 Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Application (2017-2022)
9.3.2 Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Application (2023-2028)
9.3.3 Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Application (2017-2028)
9.4 Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country
9.4.1 Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2017-2022)
9.4.2 Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size (2017-2028)
10.2 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Type
10.2.1 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Type (2017-2028)
10.3 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Application
10.3.1 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Application (2017-2028)
10.4 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country
10.4.1 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.1.4 Roche Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2017-2022)
11.1.5 Roche Recent Developments
11.2 Regeneron Pharmaceuticals
11.2.1 Regeneron Pharmaceuticals Company Details
11.2.2 Regeneron Pharmaceuticals Business Overview
11.2.3 Regeneron Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.2.4 Regeneron Pharmaceuticals Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2017-2022)
11.2.5 Regeneron Pharmaceuticals Recent Developments
11.3 Bayer
11.3.1 Bayer Company Details
11.3.2 Bayer Business Overview
11.3.3 Bayer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.3.4 Bayer Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2017-2022)
11.3.5 Bayer Recent Developments
11.4 Santen Oy
11.4.1 Santen Oy Company Details
11.4.2 Santen Oy Business Overview
11.4.3 Santen Oy Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.4.4 Santen Oy Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2017-2022)
11.4.5 Santen Oy Recent Developments
11.5 Kanghong Pharmaceuticals
11.5.1 Kanghong Pharmaceuticals Company Details
11.5.2 Kanghong Pharmaceuticals Business Overview
11.5.3 Kanghong Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.5.4 Kanghong Pharmaceuticals Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2017-2022)
11.5.5 Kanghong Pharmaceuticals Recent Developments
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.6.4 Novartis Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2017-2022)
11.6.5 Novartis Recent Developments
11.7 Eli Lilly and Company
11.7.1 Eli Lilly and Company Company Details
11.7.2 Eli Lilly and Company Business Overview
11.7.3 Eli Lilly and Company Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.7.4 Eli Lilly and Company Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2017-2022)
11.7.5 Eli Lilly and Company Recent Developments
11.8 TRACON Pharmaceuticals
11.8.1 TRACON Pharmaceuticals Company Details
11.8.2 TRACON Pharmaceuticals Business Overview
11.8.3 TRACON Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.8.4 TRACON Pharmaceuticals Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2017-2022)
11.8.5 TRACON Pharmaceuticals Recent Developments
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.9.4 Pfizer Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2017-2022)
11.9.5 Pfizer Recent Developments
11.10 GSK
11.10.1 GSK Company Details
11.10.2 GSK Business Overview
11.10.3 GSK Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.10.4 GSK Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2017-2022)
11.10.5 GSK Recent Developments
11.11 BIOCAD
11.11.1 BIOCAD Company Details
11.11.2 BIOCAD Business Overview
11.11.3 BIOCAD Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.11.4 BIOCAD Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2017-2022)
11.11.5 BIOCAD Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer